Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The Novel KIF1A Missense Variant (R169T) Strongly Reduces Microtubule Stimulated ATPase Activity and Is Associated With NESCAV Syndrome

  • Aguilera, Cinthia
  • Hümmer, Stefan
  • Masanas Jimenez, Marc
  • Gabau, Elisabeth
  • Guitart, Miriam
  • Jeyaprakash, A. Arockia
  • Segura Ginard, Miguel
  • Ruiz, Anna
  • Santamaria Margalef, Anna
Síndrome de NESCAV; Kinesina; Microtúbul, Síndrome de NESCAV; Kinesina; Microtubulo, NESCAV syndrome; Kinesin; Microtubule, KIF1A is a microtubule-dependent motor protein responsible for fast anterograde transport of synaptic vesicle precursors in neurons. Pathogenic variants in KIF1A have been associated with a wide spectrum of neurological disorders. Here, we report a patient presenting a severe neurodevelopmental disorder carrying a novel de novo missense variant p.Arg169Thr (R169T) in the KIF1A motor domain. The clinical features present in our patient match with those reported for NESCAV syndrome including severe developmental delay, spastic paraparesis, motor sensory neuropathy, bilateral optic nerve atrophy, progressive cerebellar atrophy, epilepsy, ataxia, and hypotonia. Here, we demonstrate that the microtubule-stimulated ATPase activity of the KIF1A is strongly reduced in the motor domain of the R169T variant. Supporting this, in silico structural modeling suggests that this variant impairs the interaction of the KIF1A motor domain with microtubules. The characterization of the molecular effect of the R169T variant on the KIF1A protein together with the presence of the typical clinical features indicates its causal pathogenic effect., This work was supported by the Instituto de Salud Carlos III (Grant No. PI16/01411 to MG and Grant No. CPII18/00027 to AS), the Asociación Española de Síndrome de Angelman, Institut d’investigació i innovació Parc Taulí I3PT (CIR2018/021), the Ministerio de Educación, Cultura y Deporte (Grant No. FPU16/01099 to MM), the Asociación Española Contra el Cáncer (Grant No. LABAE18009SEGU to MS), and the Centro de Investigación Biomédica en Red Cancer - CIBERONC (Grant No. CB16/12/00363 to SH). Finally, AJ was supported by the Wellcome Trust though a Senior Research Fellowship (202811).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Novel intragenic deletions within the UBE3A gene in two unrelated patients with Angelman syndrome, case report and review of the literature

  • Aguilera, Cinthia|||0000-0002-0363-8590
  • Viñas-Jornet, Marina|||0000-0002-6018-3043
  • Baena Díez, Neus|||0000-0003-0677-240X
  • Gabau, Elisabeth|||0000-0001-8120-7393
  • Fernández, Concepción
  • Capdevila, Núria|||0000-0003-2080-7381
  • Cirkovic, Sanja
  • Sarajlija, Adrijan
  • Miskovic, Marijana
  • Radivojevic, Danijela
  • Ruiz, Anna|||0000-0001-7314-5962
  • Guitart, Maria|||0000-0003-2957-7404
Patients with Angelman syndrome (AS) are affected by severe intellectual disability with absence of speech, distinctive dysmorphic craniofacial features, ataxia and a characteristic behavioral phenotype. AS is caused by the lack of expression in neurons of the UBE3A gene, which is located in the 15q11.2-q13 imprinted region. Functional loss of UBE3A is due to 15q11.2-q13 deletion, mutations in the UBE3A gene, paternal uniparental disomy and genomic imprinting defects. We report here two patients with clinical features of AS referred to our hospital for clinical follow-up and genetic diagnosis. Methylation Specific-Multiplex Ligation-Dependent Probe Amplification (MS-MLPA) of the 15q11.2-q13 region was carried out in our laboratory as the first diagnostic tool detecting two novel UBE3A intragenic deletions. Subsequently, the MLPA P336-A2 kit was used to confirm and determine the size of the UBE3A deletion in the two patients. A review of the clinical features of previously reported patients with whole UBE3A gene or partial intragenic deletions is presented here together with these two new patients. Although rare, UBE3A intragenic deletions may represent a small fraction of AS patients without a genetic diagnosis. Testing for UBE3A intragenic exonic deletions should be performed in those AS patients with a normal methylation pattern and no mutations in the UBE3A gene.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Identification of a de novo splicing variant in the Coffin-Siris gene, 1, in a patient with Angelman-like syndrome

  • Aguilera, Cinthia|||0000-0002-0363-8590
  • Gabau, Elisabeth|||0000-0001-8120-7393
  • Laurie, Steven|||0000-0003-3913-5829
  • Baena Díez, Neus|||0000-0003-0677-240X
  • Derdak, Sophia
  • Capdevila, Núria|||0000-0003-2080-7381
  • Ramírez Mallafré, Ariadna|||0000-0002-7897-816X
  • Delgadillo, Veronica
  • García-Catalan, Maria Jesus
  • Brun Gasca, Carme|||0000-0002-5651-5842
  • Guitart, Maria|||0000-0003-2957-7404
  • Ruiz, Anna|||0000-0001-7314-5962
Patients affected by Angelman syndrome (AS) present severe intellectual disability, lack of speech, ataxia, seizures, abnormal electroencephalography (EEG), and a characteristic behavioral phenotype. Around 10% of patients with a clinical diagnosis of AS(AS-like) do not have an identifiable molecular defect. Some of these patients harbor alternative genetic defects that present overlapping features with AS. Trio whole-exome sequence was performed on patient and parent's DNA extracted from peripheral blood. Exome data were filtered according to a de novo autosomal dominant inheritance. cDNA analysis was carried out to assess the effect of the splice site variant. We identified a novel heterozygous SMARCE1 splicing variant that leads to an exon skipping in a patient with an Angelman-like phenotype. Missense variants in the SMARCE1 gene are known to cause Coffin-Siris syndrome (CSS), which is a rare congenital syndrome. Clinical reevaluation of the patient confirmed the presence of characteristic clinical features of CSS, many of them overlapping with AS. Taking into account the novel finding reported in this study, we consider that CSS should be added to the expanding list of differential diagnoses for AS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Novel KIF1A Missense Variant (R169T) Strongly Reduces Microtubule Stimulated ATPase Activity and Is Associated With NESCAV Syndrome

  • Aguilera, Cinthia|||0000-0002-0363-8590
  • Hümmer, Stefan|||0000-0002-8184-3872
  • Masanas, Marc|||0000-0002-2249-8554
  • Gabau, Elisabeth|||0000-0001-8120-7393
  • Guitart, Maria|||0000-0003-2957-7404
  • Jeyaprakash, A. Arockia
  • Segura, Miguel F.|||0000-0003-0916-3618
  • Santamaría Margalef, Anna|||0000-0001-6726-8990
  • Ruiz, Anna|||0000-0001-7314-5962
KIF1A is a microtubule-dependent motor protein responsible for fast anterograde transport of synaptic vesicle precursors in neurons. Pathogenic variants in KIF1A have been associated with a wide spectrum of neurological disorders. Here, we report a patient presenting a severe neurodevelopmental disorder carrying a novel de novo missense variant p.Arg169Thr (R169T) in the KIF1A motor domain. The clinical features present in our patient match with those reported for NESCAV syndrome including severe developmental delay, spastic paraparesis, motor sensory neuropathy, bilateral optic nerve atrophy, progressive cerebellar atrophy, epilepsy, ataxia, and hypotonia. Here, we demonstrate that the microtubule-stimulated ATPase activity of the KIF1A is strongly reduced in the motor domain of the R169T variant. Supporting this, in silico structural modeling suggests that this variant impairs the interaction of the KIF1A motor domain with microtubules. The characterization of the molecular effect of the R169T variant on the KIF1A protein together with the presence of the typical clinical features indicates its causal pathogenic effect.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

New genes involved in Angelman syndrome-like, Expanding the genetic spectrum

  • Aguilera, Cinthia|||0000-0002-0363-8590
  • Gabau, Elisabeth|||0000-0001-8120-7393
  • Ramírez Mallafré, Ariadna|||0000-0002-7897-816X
  • Brun Gasca, Carme|||0000-0002-5651-5842
  • Dominguez-Carral, Jana
  • Delgadillo, Veronica
  • Laurie, Steven|||0000-0003-3913-5829
  • Derdak, Sophia
  • Padilla Sirera, Natàlia|||0000-0002-7872-2279
  • de la Cruz, Xavier|||0000-0002-9738-8472
  • Capdevila, Núria|||0000-0003-2080-7381
  • Spataro, Nino|||0000-0002-2127-2238
  • Baena Díez, Neus|||0000-0003-0677-240X
  • Guitart, Maria|||0000-0003-2957-7404
  • Ruiz, Anna|||0000-0001-7314-5962
Angelman syndrome (AS) is a neurogenetic disorder characterized by severe developmental delay with absence of speech, happy disposition, frequent laughter, hyperactivity, stereotypies, ataxia and seizures with specific EEG abnormalities. There is a 10-15% of patients with an AS phenotype whose genetic cause remains unknown (Angelman-like syndrome, AS-like). Whole-exome sequencing (WES) was performed on a cohort of 14 patients with clinical features of AS and no molecular diagnosis. As a result, we identified 10 de novo and 1 X-linked pathogenic/likely pathogenic variants in 10 neurodevelopmental genes (SYNGAP1, VAMP2, TBL1XR1, ASXL3, SATB2, SMARCE1, SPTAN1, KCNQ3, SLC6A1 and LAS1L) and one deleterious de novo variant in a candidate gene (HSF2). Our results highlight the wide genetic heterogeneity in AS-like patients and expands the differential diagnosis.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

The Novel KIF1A Missense Variant (R169T) Strongly Reduces Microtubule Stimulated ATPase Activity and Is Associated With NESCAV Syndrome

  • Aguilera, Cinthia
  • Hümmer, Stefan
  • Masanas Jimenez, Marc
  • Gabau, Elisabeth
  • Guitart, Miriam
  • Jeyaprakash, A. Arockia
  • Segura Ginard, Miguel
  • Ruiz, Anna
  • Santamaria Margalef, Anna
Síndrome de NESCAV; Kinesina; Microtúbul, Síndrome de NESCAV; Kinesina; Microtubulo, NESCAV syndrome; Kinesin; Microtubule, KIF1A is a microtubule-dependent motor protein responsible for fast anterograde transport of synaptic vesicle precursors in neurons. Pathogenic variants in KIF1A have been associated with a wide spectrum of neurological disorders. Here, we report a patient presenting a severe neurodevelopmental disorder carrying a novel de novo missense variant p.Arg169Thr (R169T) in the KIF1A motor domain. The clinical features present in our patient match with those reported for NESCAV syndrome including severe developmental delay, spastic paraparesis, motor sensory neuropathy, bilateral optic nerve atrophy, progressive cerebellar atrophy, epilepsy, ataxia, and hypotonia. Here, we demonstrate that the microtubule-stimulated ATPase activity of the KIF1A is strongly reduced in the motor domain of the R169T variant. Supporting this, in silico structural modeling suggests that this variant impairs the interaction of the KIF1A motor domain with microtubules. The characterization of the molecular effect of the R169T variant on the KIF1A protein together with the presence of the typical clinical features indicates its causal pathogenic effect., This work was supported by the Instituto de Salud Carlos III (Grant No. PI16/01411 to MG and Grant No. CPII18/00027 to AS), the Asociación Española de Síndrome de Angelman, Institut d’investigació i innovació Parc Taulí I3PT (CIR2018/021), the Ministerio de Educación, Cultura y Deporte (Grant No. FPU16/01099 to MM), the Asociación Española Contra el Cáncer (Grant No. LABAE18009SEGU to MS), and the Centro de Investigación Biomédica en Red Cancer - CIBERONC (Grant No. CB16/12/00363 to SH). Finally, AJ was supported by the Wellcome Trust though a Senior Research Fellowship (202811).